What are the recommended pharmacologic and non‑pharmacologic strategies to reduce proteinuria in a child?

Reducing Proteinuria in Children: Evidence-Based Strategies

For children with proteinuria, corticosteroids remain the cornerstone of initial therapy, with prednisone 60 mg/m²/day (maximum 60 mg) given for 4-6 weeks followed by alternate-day dosing for 2-5 months, while ACE inhibitors or ARBs should be added for blood pressure control and additional antiproteinuric effects, targeting a protein-to-creatinine ratio <200 mg/g (<20 mg/mmol). 1

Pharmacologic Strategies

First-Line: Corticosteroid Therapy

For initial presentation of nephrotic syndrome in children >1 year:

• Start with prednisone 60 mg/m²/day or 2 mg/kg/day (maximum 60 mg) as a single daily dose for 4-6 weeks 1
• Transition to alternate-day prednisone at 40 mg/m² or 1.5 mg/kg (maximum 40 mg on alternate days) for 2-5 months with gradual tapering 1
• Total treatment duration should be at least 12 weeks to reduce relapse rates (relative risk reduction of 30% with 3 months vs. 2 months of therapy) 1

For relapses in frequently relapsing or steroid-dependent nephrotic syndrome:

• Treat with daily prednisone until remission for at least 3 days, then alternate-day prednisone for at least 3 months 1
• Use the lowest dose of alternate-day prednisone to maintain remission without major adverse effects 1
• Consider daily prednisone during upper respiratory infections to reduce relapse risk in children already on alternate-day therapy 1

Renin-Angiotensin System Blockade

ACE inhibitors and ARBs are critical adjunctive therapy:

• Both losartan and enalapril reduce proteinuria by 30-40% in children with chronic kidney disease, with comparable efficacy and safety profiles 2
• These agents provide antiproteinuric effects beyond blood pressure reduction through antifibrotic and anti-inflammatory properties 3, 4
• ACE inhibitors or ARBs should be first-line antihypertensive therapy in children with proteinuria 3, 5

Blood Pressure Management

Intensified blood pressure control significantly delays progression:

• Target 24-hour mean arterial pressure below the 50th percentile (rather than 50th-95th percentile) reduces the risk of 50% GFR decline or end-stage renal disease by 35% (hazard ratio 0.65) 6
• For children with chronic kidney disease and proteinuria, aim for blood pressure at the 50th percentile for body length, age, and gender 3
• For children without proteinuria, the 75th percentile is acceptable 3
• Multiple drug therapy is often required to achieve these targets 5

Important caveat: Proteinuria commonly rebounds after initial 50% reduction despite ongoing ACE inhibition and good blood pressure control, requiring vigilant monitoring 6

Non-Pharmacologic Strategies

Dietary Modifications

Sodium restriction is essential:

• Restrict dietary sodium to <2.0 g/day (<90 mmol/day) 1
• This enhances the effectiveness of both diuretics and RAS blockade 1

Supportive Measures for Edema Management

When edema is present:

• Use loop diuretics as first-line, with twice-daily dosing preferred over once-daily 1
• For resistant edema, combine loop diuretics with thiazide-like diuretics for synergistic effect 1
• Consider adding spironolactone or amiloride to counter hypokalemia and provide additional blood pressure control 1

Treatment Goals and Monitoring

Target proteinuria levels:

• Aim for protein-to-creatinine ratio <200 mg/g (<20 mg/mmol) or <8 mg/m²/hour in 24-hour urine for any child with glomerular disease 1
• Accept higher baseline values only with kidney biopsy evidence of scarring 1
• Quantify proteinuria regularly as it has disease-specific prognostic relevance 1

Monitor for treatment complications:

• Watch for hypokalemia with thiazide and loop diuretics 1
• Monitor for hyperkalemia with ACE inhibitors/ARBs and potassium-sparing diuretics 2
• Assess renal function regularly, though both losartan and enalapril maintain eGFR without appreciable decline over 3 years 2

Clinical Pitfalls to Avoid

• Do not use corticosteroids as monotherapy in hypertensive children with proteinuria—always add RAS blockade for dual benefit 3, 6
• Do not accept suboptimal blood pressure control—achievement of blood pressure targets is an independent predictor of delayed disease progression 6
• Do not discontinue ACE inhibitors when proteinuria rebounds—this is common and expected; maintain therapy while optimizing other interventions 6
• Children <1 year require different management—they likely have genetic causes and should not receive standard corticosteroid protocols 1